SAR-443216

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSAR-443216
Drug Alias NameSAR-443216
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsT cell surface glycoprotein CD3 stimulantsImmunologic cytotoxicity +[5] 
TargetsT-cell-specific surface glycoprotein CD28T cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursLung NeoplasmsStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis Recherche & DeveloppementSanofi (China) Investment Co Ltd
Inactive CompaniesSanofi
Active IndicationsSolid tumours
Inactive IndicationsLung NeoplasmsStomach NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A